Symbols / SCYX Stock $1.03 +0.19% SCYNEXIS, Inc.
SCYX (Stock) Chart
About
SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
Stock Fundamentals
Scroll to Statements| Market Cap | 46.09M | Enterprise Value | 8.15M | Income | -8.61M | Sales | 20.60M | Book/sh | 1.13 | Cash/sh | 0.90 |
| Dividend Yield | — | Payout | 0.00% | Employees | 18 | IPO | — | P/E | — | Forward P/E | -4.13 |
| PEG | — | P/S | 2.24 | P/B | 0.91 | P/C | — | EV/EBITDA | — | EV/Sales | 0.40 |
| Quick Ratio | 6.98 | Current Ratio | 7.04 | Debt/Eq | 4.41 | LT Debt/Eq | — | EPS (ttm) | -0.17 | EPS next Y | -0.25 |
| EPS Growth | — | Revenue Growth | 18.09% | Earnings | 2026-05-15 | ROA | -13.43% | ROE | -16.48% | ROIC | — |
| Gross Margin | 100.00% | Oper. Margin | 56.43% | Profit Margin | -41.79% | Shs Outstand | 44.66M | Shs Float | 22.82M | Short Float | 3.38% |
| Short Ratio | 1.47 | Short Interest | — | 52W High | 1.31 | 52W Low | 0.56 | Beta | 1.15 | Avg Volume | 567.31K |
| Volume | 15.87K | Target Price | $3.47 | Recom | Strong_buy | Prev Close | $1.03 | Price | $1.03 | Change | 0.19% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-28 | main | Guggenheim | Buy → Buy | $3 |
| 2024-04-01 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2023-08-15 | reit | Cantor Fitzgerald | Overweight → Overweight | $15 |
| 2023-04-03 | main | Guggenheim | — → Buy | $9 |
| 2023-04-03 | reit | Ladenburg Thalmann | — → Buy | $15 |
| 2023-03-01 | init | Guggenheim | — → Buy | $8 |
| 2022-05-13 | main | HC Wainwright & Co. | — → Buy | $8 |
| 2022-03-31 | main | HC Wainwright & Co. | — → Buy | $14 |
| 2021-06-07 | main | Aegis Capital | — → Buy | $35 |
| 2021-04-12 | main | Aegis Capital | — → Buy | $40 |
| 2021-01-22 | init | Guggenheim | — → Buy | $25 |
| 2021-01-06 | init | Cantor Fitzgerald | — → Overweight | $30 |
| 2020-12-28 | reit | HC Wainwright & Co. | — → Buy | $20 |
| 2020-04-23 | main | Aegis Capital | — → Buy | $5 |
| 2018-10-16 | main | Maxim Group | Buy → Buy | $4 |
| 2018-06-27 | init | Maxim Group | — → Buy | $6 |
| 2018-05-24 | init | Ladenburg Thalmann | — → Buy | $9 |
| 2018-04-10 | init | Seaport Global | — → Buy | $4 |
| 2017-10-24 | init | Guggenheim | — → Buy | $6 |
| 2017-01-31 | init | Aegis Capital | — → Buy | $7 |
- SCYX SCYNEXIS Inc. reports 87.3 percent Q4 2025 EPS beat, shares climb 5.71 percent in today’s trading. - Cổng thông tin điện tử tỉnh Tây Ninh hu, 23 Apr 2026 00
- Director Steven Gilman to retire from SCYNEXIS (NASDAQ: SCYX) Board - Stock Titan Mon, 20 Apr 2026 20
- Scynexis In Spotlight After Poxel Deal, $40 Million Private Placement – SCYX Stock Climbs 2% Pre-Market - Stocktwits ue, 31 Mar 2026 07
- SCYNEXIS Director Steven Gilman Announces Board Retirement - TipRanks Mon, 20 Apr 2026 20
- SCYNEXIS lands cash to fund rare disease drug work into mid-2029 - Stock Titan ue, 31 Mar 2026 07
- Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn Situation - Yahoo Finance Mon, 10 Nov 2025 08
- SCYX Should I Buy - Intellectia AI Fri, 17 Apr 2026 07
- Brookline Capital cuts SCYNEXIS stock price target on valuation - Investing.com Mon, 09 Mar 2026 07
- SCYNEXIS, Inc. (SCYX) Discusses Transformative Asset Acquisition and Strategic Shift Toward ADPKD Therapeutics - Slideshow (NASDAQ:SCYX) 2026-04-01 - Seeking Alpha Wed, 01 Apr 2026 07
- SCYNEXIS (NASDAQ: SCYX) seeks shareholder votes on plan increase and authorized shares - Stock Titan Mon, 20 Apr 2026 21
- Kidney disease drug with Phase 2 study due this year joins SCYNEXIS - Stock Titan ue, 31 Mar 2026 07
- SCYNEXIS (NASDAQ: SCYX) asks shareholders to approve 1-for-5–1-for-10 reverse split - Stock Titan Fri, 17 Apr 2026 20
- SCYNEXIS (SCYX) CEO joins private placement, adds stock and warrants - Stock Titan hu, 02 Apr 2026 07
- Squadron Fund holds 9.6% of SCYNEXIS (NASDAQ: SCYX) - Stock Titan Wed, 08 Apr 2026 07
- Great Point Partners (SCYX) reports 9.99% ownership, joint filing details - Stock Titan ue, 07 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
20.60
+449.95%
|
3.75
-97.33%
|
140.14
+2652.72%
|
5.09
|
| Operating Revenue |
|
20.60
+449.95%
|
3.75
-97.33%
|
140.14
+2652.72%
|
5.09
|
| Cost Of Revenue |
|
—
|
0.00
-100.00%
|
15.62
+2387.90%
|
0.63
|
| Reconciled Cost Of Revenue |
|
—
|
0.00
-100.00%
|
15.62
+2387.90%
|
0.63
|
| Gross Profit |
|
—
|
3.75
-96.99%
|
124.52
+2689.98%
|
4.46
|
| Operating Expense |
|
36.67
-10.25%
|
40.86
-21.19%
|
51.85
-42.53%
|
90.22
|
| Research And Development |
|
22.28
-15.62%
|
26.41
-14.62%
|
30.93
+13.46%
|
27.26
|
| Selling General And Administration |
|
14.39
-0.44%
|
14.46
-30.89%
|
20.92
-66.77%
|
62.96
|
| Total Expenses |
|
36.67
-10.25%
|
40.86
-39.44%
|
67.47
-25.73%
|
90.85
|
| Operating Income |
|
-16.07
+56.69%
|
-37.12
-151.08%
|
72.67
+184.74%
|
-85.76
|
| Total Operating Income As Reported |
|
-16.07
+56.69%
|
-37.12
-151.08%
|
72.67
+184.74%
|
-85.76
|
| EBITDA |
|
-8.44
+58.46%
|
-20.31
-128.65%
|
70.89
+214.88%
|
-61.70
|
| Normalized EBITDA |
|
-14.21
+58.59%
|
-34.32
-146.24%
|
74.21
+186.98%
|
-85.32
|
| Reconciled Depreciation |
|
—
|
0.00
-100.00%
|
0.58
-4.29%
|
0.61
|
| EBIT |
|
-8.44
+58.46%
|
-20.31
-128.89%
|
70.31
+212.84%
|
-62.31
|
| Total Unusual Items |
|
5.77
-58.79%
|
14.01
+521.93%
|
-3.32
-114.06%
|
23.62
|
| Total Unusual Items Excluding Goodwill |
|
5.77
-58.79%
|
14.01
+521.93%
|
-3.32
-114.06%
|
23.62
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-8.61
+59.56%
|
-21.29
-131.75%
|
67.04
+206.74%
|
-62.81
|
| Pretax Income |
|
-8.61
+59.27%
|
-21.14
-131.46%
|
67.18
+199.51%
|
-67.51
|
| Net Non Operating Interest Income Expense |
|
1.69
-2.59%
|
1.74
+180.05%
|
-2.17
+59.61%
|
-5.37
|
| Interest Expense Non Operating |
|
0.17
-79.11%
|
0.83
-73.55%
|
3.13
-39.78%
|
5.20
|
| Net Interest Income |
|
1.69
-2.59%
|
1.74
+180.05%
|
-2.17
+59.61%
|
-5.37
|
| Interest Expense |
|
0.17
-79.11%
|
0.83
-73.55%
|
3.13
-39.78%
|
5.20
|
| Interest Income Non Operating |
|
2.18
-49.27%
|
4.29
+8.52%
|
3.95
+179.43%
|
1.42
|
| Interest Income |
|
2.18
-49.27%
|
4.29
+8.52%
|
3.95
+179.43%
|
1.42
|
| Other Income Expense |
|
5.77
-59.47%
|
14.24
+529.01%
|
-3.32
-114.06%
|
23.62
|
| Other Non Operating Income Expenses |
|
—
|
0.23
|
—
|
0.00
|
| Gain On Sale Of Security |
|
5.77
-58.79%
|
14.01
+521.93%
|
-3.32
-114.06%
|
23.62
|
| Tax Provision |
|
0.00
-100.00%
|
0.15
+9.42%
|
0.14
+102.94%
|
-4.70
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
+20900.00%
|
0.00
-98.56%
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
-100.00%
|
2.94
+88704.82%
|
-0.00
-100.20%
|
1.64
|
| Net Income Including Noncontrolling Interests |
|
-8.61
+59.56%
|
-21.29
-131.75%
|
67.04
+206.74%
|
-62.81
|
| Net Income From Continuing Operation Net Minority Interest |
|
-8.61
+59.56%
|
-21.29
-131.75%
|
67.04
+206.74%
|
-62.81
|
| Net Income From Continuing And Discontinued Operation |
|
-8.61
+59.56%
|
-21.29
-131.75%
|
67.04
+206.74%
|
-62.81
|
| Net Income Continuous Operations |
|
-8.61
+59.56%
|
-21.29
-131.75%
|
67.04
+206.74%
|
-62.81
|
| Normalized Income |
|
-14.38
+55.55%
|
-32.35
-145.99%
|
70.36
+182.99%
|
-84.78
|
| Net Income Common Stockholders |
|
-8.61
+59.56%
|
-21.29
-131.75%
|
67.04
+206.74%
|
-62.81
|
| Diluted EPS |
|
-0.17
+61.36%
|
-0.44
-131.65%
|
1.39
+194.56%
|
-1.47
|
| Basic EPS |
|
-0.17
+61.36%
|
-0.44
-131.43%
|
1.40
+195.24%
|
-1.47
|
| Basic Average Shares |
|
49.93
+2.93%
|
48.51
+1.38%
|
47.85
+12.29%
|
42.61
|
| Diluted Average Shares |
|
49.93
+2.93%
|
48.51
+0.25%
|
48.39
+13.56%
|
42.61
|
| Diluted NI Availto Com Stockholders |
|
-8.61
+59.56%
|
-21.29
-131.75%
|
67.04
+206.74%
|
-62.81
|
| Other Taxes |
|
—
|
—
|
—
|
—
|
| Total Other Finance Cost |
|
0.31
-81.92%
|
1.73
-42.35%
|
2.99
+88.42%
|
1.59
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
59.03
-34.88%
|
90.64
-29.41%
|
128.41
+46.24%
|
87.81
|
| Current Assets |
|
40.37
-44.07%
|
72.18
-29.31%
|
102.12
+29.16%
|
79.06
|
| Cash Cash Equivalents And Short Term Investments |
|
40.03
-32.49%
|
59.30
-20.25%
|
74.36
+1.17%
|
73.50
|
| Cash And Cash Equivalents |
|
21.26
+32.45%
|
16.05
-52.86%
|
34.05
-25.68%
|
45.81
|
| Other Short Term Investments |
|
18.77
-56.60%
|
43.25
+7.29%
|
40.31
+45.59%
|
27.69
|
| Receivables |
|
0.00
-100.00%
|
10.26
-52.98%
|
21.83
+938.84%
|
2.10
|
| Accounts Receivable |
|
—
|
—
|
0.00
-100.00%
|
2.10
|
| Other Receivables |
|
—
|
10.26
-52.98%
|
21.83
|
—
|
| Inventory |
|
—
|
—
|
0.00
-100.00%
|
0.90
|
| Raw Materials |
|
—
|
—
|
0.00
-100.00%
|
0.27
|
| Work In Process |
|
—
|
—
|
0.00
-100.00%
|
0.61
|
| Finished Goods |
|
—
|
—
|
0.00
-100.00%
|
0.02
|
| Prepaid Assets |
|
0.25
-74.11%
|
0.95
+47.98%
|
0.64
-73.70%
|
2.44
|
| Restricted Cash |
|
0.08
-81.61%
|
0.43
+14.47%
|
0.38
+590.91%
|
0.06
|
| Other Current Assets |
|
0.02
-98.62%
|
1.23
-74.85%
|
4.91
+7812.90%
|
0.06
|
| Total Non Current Assets |
|
18.65
+1.03%
|
18.46
-29.79%
|
26.30
+200.56%
|
8.75
|
| Net PPE |
|
1.76
-15.60%
|
2.09
-11.59%
|
2.36
-8.87%
|
2.59
|
| Gross PPE |
|
1.76
-15.60%
|
2.09
-11.59%
|
2.36
-8.87%
|
2.59
|
| Accumulated Depreciation |
|
—
|
—
|
—
|
—
|
| Machinery Furniture Equipment |
|
—
|
—
|
—
|
—
|
| Other Properties |
|
1.76
-15.60%
|
2.09
-11.59%
|
2.36
-8.87%
|
2.59
|
| Goodwill And Other Intangible Assets |
|
—
|
—
|
0.00
-100.00%
|
0.41
|
| Investments And Advances |
|
16.25
+2.53%
|
15.85
-32.84%
|
23.59
|
0.00
|
| Non Current Deferred Assets |
|
0.53
+27.82%
|
0.42
+138.29%
|
0.17
+139.73%
|
0.07
|
| Other Non Current Assets |
|
0.11
+0.00%
|
0.11
-33.13%
|
0.16
-97.13%
|
5.67
|
| Total Liabilities Net Minority Interest |
|
9.65
-72.86%
|
35.57
-35.86%
|
55.45
-34.44%
|
84.58
|
| Current Liabilities |
|
5.73
-76.21%
|
24.10
+47.82%
|
16.30
-7.46%
|
17.62
|
| Payables And Accrued Expenses |
|
3.51
-46.83%
|
6.60
-49.05%
|
12.95
+40.04%
|
9.25
|
| Payables |
|
2.23
-51.30%
|
4.57
-36.09%
|
7.15
+20.41%
|
5.94
|
| Accounts Payable |
|
2.23
-51.30%
|
4.57
-36.09%
|
7.15
+20.41%
|
5.94
|
| Current Accrued Expenses |
|
1.28
-36.75%
|
2.03
-65.02%
|
5.80
+75.21%
|
3.31
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
1.51
-14.52%
|
1.76
+4.20%
|
1.69
-26.94%
|
2.32
|
| Current Debt And Capital Lease Obligation |
|
0.48
-96.57%
|
14.10
+4045.59%
|
0.34
+20.57%
|
0.28
|
| Current Debt |
|
—
|
13.69
|
—
|
—
|
| Other Current Borrowings |
|
—
|
13.69
|
—
|
—
|
| Current Capital Lease Obligation |
|
0.48
+18.67%
|
0.41
+19.71%
|
0.34
+20.57%
|
0.28
|
| Current Deferred Liabilities |
|
0.23
-85.69%
|
1.64
+38.10%
|
1.19
|
0.00
|
| Current Deferred Revenue |
|
0.23
-85.69%
|
1.64
+38.10%
|
1.19
|
0.00
|
| Other Current Liabilities |
|
—
|
—
|
0.13
-97.75%
|
5.77
|
| Total Non Current Liabilities Net Minority Interest |
|
3.92
-65.84%
|
11.47
-70.71%
|
39.15
-41.54%
|
66.96
|
| Long Term Debt And Capital Lease Obligation |
|
1.69
-22.21%
|
2.17
-85.24%
|
14.74
-69.49%
|
48.31
|
| Long Term Debt |
|
—
|
—
|
12.16
-73.21%
|
45.39
|
| Long Term Capital Lease Obligation |
|
1.69
-22.21%
|
2.17
-15.73%
|
2.58
-11.64%
|
2.92
|
| Non Current Deferred Liabilities |
|
0.00
-100.00%
|
1.29
-52.55%
|
2.73
|
0.00
|
| Non Current Deferred Revenue |
|
0.00
-100.00%
|
1.29
-52.55%
|
2.73
|
0.00
|
| Other Non Current Liabilities |
|
—
|
—
|
—
|
—
|
| Stockholders Equity |
|
49.38
-10.35%
|
55.08
-24.51%
|
72.96
+2156.79%
|
3.23
|
| Common Stock Equity |
|
49.38
-10.35%
|
55.08
-24.51%
|
72.96
+2156.79%
|
3.23
|
| Capital Stock |
|
0.05
+12.20%
|
0.04
+2.50%
|
0.04
+11.11%
|
0.04
|
| Common Stock |
|
0.05
+12.20%
|
0.04
+2.50%
|
0.04
+11.11%
|
0.04
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
43.54
+14.66%
|
37.97
+2.06%
|
37.21
+13.85%
|
32.68
|
| Ordinary Shares Number |
|
43.54
+14.66%
|
37.97
+2.06%
|
37.21
+13.85%
|
32.68
|
| Additional Paid In Capital |
|
434.47
+0.67%
|
431.57
+0.79%
|
428.17
+0.63%
|
425.49
|
| Retained Earnings |
|
-385.14
-2.29%
|
-376.54
-5.99%
|
-355.25
+15.88%
|
-422.29
|
| Total Equity Gross Minority Interest |
|
49.38
-10.35%
|
55.08
-24.51%
|
72.96
+2156.79%
|
3.23
|
| Total Capitalization |
|
49.38
-10.35%
|
55.08
-35.30%
|
85.12
+75.05%
|
48.63
|
| Working Capital |
|
34.64
-27.96%
|
48.08
-43.97%
|
85.81
+39.66%
|
61.44
|
| Invested Capital |
|
49.38
-28.20%
|
68.77
-19.21%
|
85.12
+75.05%
|
48.63
|
| Total Debt |
|
2.17
-86.63%
|
16.27
+7.89%
|
15.08
-68.97%
|
48.60
|
| Capital Lease Obligations |
|
2.17
-15.76%
|
2.58
-11.61%
|
2.92
-8.80%
|
3.20
|
| Net Tangible Assets |
|
49.38
-10.35%
|
55.08
-24.51%
|
72.96
+2482.73%
|
2.83
|
| Tangible Book Value |
|
49.38
-10.35%
|
55.08
-24.51%
|
72.96
+2482.73%
|
2.83
|
| Derivative Product Liabilities |
|
2.23
-72.18%
|
8.00
-63.11%
|
21.68
+16.28%
|
18.64
|
| Held To Maturity Securities |
|
16.25
+2.53%
|
15.85
-32.84%
|
23.59
|
0.00
|
| Investmentin Financial Assets |
|
16.25
+2.53%
|
15.85
-32.84%
|
23.59
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-5.28
+78.00%
|
-24.01
-139.91%
|
60.16
+175.31%
|
-79.88
|
| Cash Flow From Continuing Operating Activities |
|
-5.28
+78.00%
|
-24.01
-139.91%
|
60.16
+175.31%
|
-79.88
|
| Net Income From Continuing Operations |
|
-8.61
+59.56%
|
-21.29
-131.75%
|
67.04
+206.74%
|
-62.81
|
| Depreciation Amortization Depletion |
|
—
|
0.00
-100.00%
|
0.58
-4.29%
|
0.61
|
| Depreciation And Amortization |
|
—
|
0.00
-100.00%
|
0.58
-4.29%
|
0.61
|
| Other Non Cash Items |
|
0.64
-68.07%
|
2.00
-38.03%
|
3.22
+79.51%
|
1.80
|
| Stock Based Compensation |
|
2.85
-14.76%
|
3.35
+27.52%
|
2.62
-28.81%
|
3.69
|
| Asset Impairment Charge |
|
—
|
0.00
-100.00%
|
15.35
|
0.00
|
| Operating Gains Losses |
|
-5.77
+58.79%
|
-14.01
-521.93%
|
3.32
+114.06%
|
-23.62
|
| Gain Loss On Investment Securities |
|
-5.77
+58.79%
|
-14.01
-521.93%
|
3.32
+114.06%
|
-23.62
|
| Change In Working Capital |
|
6.08
-16.48%
|
7.28
+123.77%
|
-30.64
-4110.99%
|
0.76
|
| Change In Receivables |
|
10.26
-11.26%
|
11.56
+158.63%
|
-19.73
-1490.73%
|
-1.24
|
| Changes In Account Receivables |
|
—
|
0.00
-100.00%
|
2.10
+269.44%
|
-1.24
|
| Change In Inventory |
|
—
|
0.00
+100.00%
|
-8.85
-1929.59%
|
-0.44
|
| Change In Prepaid Assets |
|
2.17
-36.07%
|
3.39
+214.04%
|
-2.97
-281.60%
|
1.64
|
| Change In Payables And Accrued Expense |
|
-3.24
+49.05%
|
-6.35
-309.05%
|
3.04
+295.87%
|
-1.55
|
| Change In Accrued Expense |
|
-1.00
+72.93%
|
-3.70
-298.34%
|
1.87
+2765.71%
|
-0.07
|
| Change In Payable |
|
-2.23
+15.70%
|
-2.65
-326.11%
|
1.17
+179.14%
|
-1.48
|
| Change In Account Payable |
|
-2.23
+15.70%
|
-2.65
-326.11%
|
1.17
+179.14%
|
-1.48
|
| Change In Other Working Capital |
|
-2.70
-176.00%
|
-0.98
-125.00%
|
3.92
|
—
|
| Change In Other Current Liabilities |
|
-0.41
-20.06%
|
-0.34
+94.40%
|
-6.05
-357.03%
|
2.35
|
| Investing Cash Flow |
|
24.31
+295.22%
|
6.15
+117.63%
|
-34.88
-27.34%
|
-27.39
|
| Cash Flow From Continuing Investing Activities |
|
24.31
+295.22%
|
6.15
+117.63%
|
-34.88
-27.34%
|
-27.39
|
| Net PPE Purchase And Sale |
|
—
|
—
|
—
|
—
|
| Purchase Of PPE |
|
—
|
—
|
—
|
—
|
| Capital Expenditure |
|
—
|
—
|
—
|
-0.01
|
| Net Investment Purchase And Sale |
|
24.31
+295.22%
|
6.15
+117.63%
|
-34.88
-27.38%
|
-27.38
|
| Purchase Of Investment |
|
-18.90
+48.09%
|
-36.42
+57.40%
|
-85.48
-212.20%
|
-27.38
|
| Sale Of Investment |
|
43.21
+1.51%
|
42.57
-15.88%
|
50.60
|
0.00
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
+100.00%
|
-0.01
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
+100.00%
|
-0.01
|
| Financing Cash Flow |
|
-14.17
-10094.24%
|
-0.14
+99.62%
|
-36.72
-175.55%
|
48.60
|
| Cash Flow From Continuing Financing Activities |
|
-14.17
-10094.24%
|
-0.14
+99.62%
|
-36.72
-175.55%
|
48.60
|
| Net Issuance Payments Of Debt |
|
-14.00
|
0.00
+100.00%
|
-36.65
-832.92%
|
5.00
|
| Issuance Of Debt |
|
—
|
—
|
0.00
-100.00%
|
5.00
|
| Repayment Of Debt |
|
-14.00
|
0.00
+100.00%
|
-36.65
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
5.00
|
| Long Term Debt Payments |
|
-14.00
|
0.00
+100.00%
|
-36.65
|
0.00
|
| Net Long Term Debt Issuance |
|
-14.00
|
0.00
+100.00%
|
-36.65
-832.92%
|
5.00
|
| Net Common Stock Issuance |
|
0.01
|
0.00
-100.00%
|
0.02
-99.96%
|
47.25
|
| Proceeds From Stock Option Exercised |
|
0.05
-8.93%
|
0.06
+33.33%
|
0.04
+133.33%
|
0.02
|
| Net Other Financing Charges |
|
-0.23
-15.90%
|
-0.20
-44.44%
|
-0.14
+96.32%
|
-3.66
|
| Changes In Cash |
|
4.85
+126.96%
|
-18.00
-57.34%
|
-11.44
+80.50%
|
-58.67
|
| Beginning Cash Position |
|
16.59
-52.03%
|
34.59
-24.85%
|
46.03
-56.04%
|
104.70
|
| End Cash Position |
|
21.45
+29.24%
|
16.59
-52.03%
|
34.59
-24.85%
|
46.03
|
| Free Cash Flow |
|
-5.28
+78.00%
|
-24.01
-139.91%
|
60.16
+175.30%
|
-79.89
|
| Interest Paid Supplemental Data |
|
0.42
-50.00%
|
0.84
-74.14%
|
3.25
-37.42%
|
5.19
|
| Amortization Of Securities |
|
-0.47
+64.63%
|
-1.34
+0.00%
|
-1.34
-333.66%
|
-0.31
|
| Common Stock Issuance |
|
0.01
|
0.00
-100.00%
|
0.02
-99.96%
|
47.25
|
| Issuance Of Capital Stock |
|
0.01
|
0.00
-100.00%
|
0.02
-99.96%
|
47.25
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-20 View
- 42026-04-02 View
- 8-K2026-03-31 View
- 8-K2026-03-31 View
- 8-K2026-03-31 View
- 10-K2026-03-04 View
- 42026-02-02 View
- 42026-02-02 View
- 42026-02-02 View
- 10-Q2025-11-05 View
- 42025-10-21 View
- 8-K2025-10-15 View
- 10-Q2025-08-13 View
- 8-K2025-07-01 View
- 42025-06-30 View
- 42025-06-30 View
- 42025-06-30 View
- 42025-06-30 View
- 42025-06-30 View
- 42025-06-30 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|